IVC Wealth Advisors LLC Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

IVC Wealth Advisors LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 12.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,476 shares of the biopharmaceutical company’s stock after selling 1,479 shares during the period. IVC Wealth Advisors LLC’s holdings in Pfizer were worth $278,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Teamwork Financial Advisors LLC purchased a new stake in Pfizer during the fourth quarter valued at about $1,204,000. True North Advisors LLC grew its holdings in shares of Pfizer by 1.3% during the 4th quarter. True North Advisors LLC now owns 52,588 shares of the biopharmaceutical company’s stock worth $1,395,000 after purchasing an additional 666 shares during the period. Kelleher Financial Advisors increased its position in Pfizer by 3.2% during the 4th quarter. Kelleher Financial Advisors now owns 35,357 shares of the biopharmaceutical company’s stock worth $938,000 after purchasing an additional 1,088 shares in the last quarter. Viking Fund Management LLC raised its holdings in Pfizer by 11.6% in the fourth quarter. Viking Fund Management LLC now owns 384,000 shares of the biopharmaceutical company’s stock valued at $10,188,000 after buying an additional 40,000 shares during the period. Finally, MBM Wealth Consultants LLC lifted its position in Pfizer by 8.5% during the fourth quarter. MBM Wealth Consultants LLC now owns 9,347 shares of the biopharmaceutical company’s stock valued at $249,000 after buying an additional 729 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on PFE shares. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup began coverage on Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Finally, StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Price Performance

PFE opened at $26.46 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a 50-day moving average of $26.07 and a 200-day moving average of $27.96. The company has a market capitalization of $149.94 billion, a P/E ratio of 35.75, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.50%. Pfizer’s payout ratio is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.